This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Chelsea Therapeutics: Northera FDA Panel Live Blog

A panel of experts is debating the merits of Chelsea's drug as a treatment for a debilitating form of low blood pressure. Follow along with our live blog.

Unigene Faces Do-or-Die FDA Panel Tuesday

An FDA panel's decision on the safety of calcitonin to treat osteoporosis will have a big impact on Unigene's stock price.

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

TheStreet contributor Aafia Chaudhry says prior study results raise the risk of a bad outcome in Ziopharm's phase III sarcoma drug trial.

Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied

Eteplirsen data are biased and flimsy, and FDA will ask for another clinical trial, says TheStreet contributor Aafia Chaudhry.

Depomed Bear Case: FDA Panel Will Ding Serada

New contributor Aafia Chaudhry explains why she believes Depomed's hot flash drug has no future.

Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs